The Atlantic's 'Longevity Scam': Four Claims Checked Against Primary Sources
The Atlantic raises valid questions about screening, peptides, off-label drugs, and compounded products. We checked those points against FDA and radiology guidance.
Review note, August 28, 2026: We corrected the publication date, identified the source as journalism and commentary rather than a scientific review, and checked its actionable claims against primary regulatory and professional guidance.
The Atlantic’s article was published on February 19, 2026 and written by sports medicine physician Jordan D. Metzl. It argues that useful prevention is being mixed with tests and treatments whose marketing can run ahead of evidence.
The piece is a critique, not a systematic review or clinical guideline. Its value is in the questions it raises. The four checks below show where current primary sources support caution and where a headline cannot settle an individual medical decision.
Claim 1: screening an asymptomatic person with total-body MRI is not established preventive care
Primary-source check: Supported.
The American College of Radiology says there is insufficient evidence to recommend total-body MRI screening for people without symptoms, risk factors, or a relevant family history. It also notes that no evidence has documented longer life from this screening and warns that nonspecific findings can lead to unnecessary follow-up.
This does not mean every MRI is inappropriate. It means a clinic should explain the indication, likely incidental findings, downstream testing, and who will manage the results before selling a scan as a general longevity intervention.
Claim 2: BPC-157 should not be presented as a routine, established therapy
Primary-source check: Supported.
The FDA includes BPC-157 on its list of bulk substances that may present significant safety risks in compounding. The agency cites limited safety information and concerns related to immunogenicity and peptide impurities.
For a patient, the useful questions are direct: Is the product approved? Why is it being recommended? Who made it? What human safety data support the route and dose? What happens if an adverse event occurs?
Claim 3: off-label prescribing is not the same as an FDA-approved longevity indication
Primary-source check: Supported, with an important distinction.
The FDA’s patient guidance explains that clinicians may generally prescribe an approved drug for an unapproved use when they judge it medically appropriate. It also explains that the FDA has not determined that the drug is safe and effective for that specific use.
Therefore, the words off-label do not by themselves prove that care is bad or unlawful. They do mean the clinic should disclose the evidence level, alternatives, known risks, monitoring plan, and uncertainty for the proposed use.
Claim 4: compounded products do not pass through FDA premarket approval
Primary-source check: Supported.
The FDA states that compounded drugs are not FDA-approved. The agency does not verify their safety, effectiveness, or quality before marketing. It also warns that poor compounding can cause contamination or incorrect potency, with the potential for serious injury or death.
Compounding can meet a legitimate patient need when an approved product is unsuitable. It should not be described as equivalent to an approved drug without explaining the regulatory and quality difference.
What the article cannot prove
The Atlantic article does not establish that every longevity clinic is deceptive, that every off-label prescription is inappropriate, or that a high price proves poor care. It also does not measure outcomes across clinics.
A more reliable clinic assessment looks for process evidence:
- a named, licensed clinician responsible for medical decisions
- a written indication for each test or treatment
- clear labels for approved, off-label, compounded, and investigational interventions
- expected benefit stated as an outcome, not just a biomarker change
- contraindications, stop rules, and adverse-event reporting
- a follow-up plan and access to complete medical records
The headline is a warning about incentives. The decision still needs intervention-specific evidence and patient-specific clinical judgment.
Main source: The Atlantic, “The Longevity Scam”, published February 19, 2026. Regulatory checks use current FDA pages and the American College of Radiology statement linked above.